Bioasis reports thai its lead investigational candidate xB3-001 demonstrated increased brain activity in a pre-clinical mouse microdialysis study. The study demonstrated that following a single intravenous treatment, xB3-001 elicited significant increases in brain cortical dopamine and serotonin activity levels at 60-90 minutes after treatment.

Bioasis is developing  the xB3 TM platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases.

PowerPoint presentation